Navigation Links
Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
Date:1/31/2008

WASHINGTON, Jan. 31 /PRNewswire/ -- The FDA approved Tibotec Pharmaceutical's novel non-nucleoside reverse transcriptase inhibitor (NNRTI) INTELENCE(R). The company also announced introductory pricing for the eagerly anticipated new compound at $21.80 per day, substantially lower than other recently introduced antiretrovirals.

"The efficacy that INTELENCE (TMC125/etravirine) has shown in the DUET studies is impressive. INTELENCE is an important new HIV medication that, for the first time, re-opens the NNRTI class to patients with NNRTI-resistant virus," stated Donna Christian-Chistensen, MD, Chair of the Congressional Black Caucus Health Brain Trust and TIICANN board member. "We applaud Tibotec for its efforts to make this innovative new medication available and accessible to people living with HIV."

In the Duet study, 612 patients were randomized and treated (304 in the TMC125 group, 308 in the placebo group). At week 24, 170 (56%) patients in the TMC125 group and 119 (39%) patients in the placebo group achieved a confirmed viral load of less than 50 copies per mL (difference in response rates 17%; 95% CI 9-25; p=0 005). Most adverse events were mild or moderate in severity. The type and incidence of adverse events, including neuropsychiatric events, seen with TMC125 were generally comparable with placebo, with the exception of rash (61 [20%] patients on TMC125 vs 30 [10%] on placebo) and diarrhea (36 [12%] patients on TMC125 vs 63 [20%] on placebo).

"As a long time member of the Fair Price Coalition, I must recognize the transparency, understanding and respect exhibited by Tibotec in its relations with the HIV/AIDS community," said Bill Arnold, Executive Director of TIICANN. "It is remarkable that Tibotec remains collegial in the broadest sense of that word in the face of the challenges being faced by its parent company, Johnson & Johnson."

"As a patient with a remarkably low tolerance for most antiretrovirals, I have always depended on NNRTIs as the base of my regimens," admitted Gary Rose, TIICANN's Chair. "It is a major relief for me to have a new option as my present regimen combining an NNRTI and a protease inhibitor which is both toxic and weakening. I think this is quite a common phenomena among patients with long-term exposure to antiretrovirals and so Tibotec's determination to develop new, non-cross resistant drugs for HIV, and just as importantly, oral compounds for hepatitis C - the company's dedication to virology is notable - is a cause for quiet celebration among infectious disease doctors and my fellow patients."

Congressman Maurice Hinchey, a TII CANN Board member stated: "Representing New York, which continues to bear the largest portion of the many burdens of the American AIDS epidemic, I'm very sensitive to any efforts to make new treatments affordable and accessible to all regardless of their financial circumstances or health insurance coverage. No HIV+ or AIDS patient should be denied access to critical drugs that can help them live longer and more productive lives."

Contact: Bill Arnold (202) 588-1775


'/>"/>
SOURCE The AIDS Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Amylin Pharmaceuticals Reports 2007 Financial Results
5. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
6. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
7. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
8. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
9. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
10. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
11. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology: